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Abstract 
Lymphocyte cytosolic protein 1 (LCP1), a member of actin-binding protein of the plastin 
family, has been identified in several malignant tumors of non-hematopoietic sites, such 
as the colon, prostate, and breast. However, little is known about the roles of LCP1 in 
oral squamous cell carcinomas (OSCCs). This present study sought to clarify the clinical 
relevance of LCP1 in OSCCs and investigate possible clinical applications for treating 
OSCCs by regulating LCP1 expression. We found up-regulation of LCP1in OSCCs 
compared with normal counterparts using real-time quantitative reverse transcription 
polymerase chain reaction (qRT-PCR), immunoblotting, and immunohistochemistry (P < 
0.05). We used shRNA models for LCP1 (shLCP1) and enoxacin (ENX), a 
fluoroquinolone antibiotic drug, as a regulator of LCP1 expression. In addition to the 
LCP1 knockdown experiments in which shLCP1 cells showed several depressed 
functions, including cellular proliferation, invasiveness, and migratory activities, 
ENX-treated cells also had attenuated functions. Consistent with our hypothesis from our 
in vitro data, LCP1-positive OSCC samples were correlated closely with the primary 
tumoral size and regional lymph node metastasis. These results suggested that LCP1 is a 
useful biomarker for determining progression of OSCCs and that ENX might be a new 
therapeutic agent for treating OSCCs by controlling LCP1 expression.  
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Introduction 
The plastin family, which is comprised of actin-binding proteins, is conserved 
evolutionary and expressed in such as yeast, plant, and animal cells1. Three isoforms of 
plastin (T-, I-, and L-types) have been identified in mammals. Among them, L-plastin, 
lymphocyte cytosolic protein 1 (LCP1), is expressed in hematopoietic cellular lineages 
and many types of cancers1. While many kinds of the actin-binding proteins modulate 
dynamics of the actin cytoskeleton, recent studies have concerned LCP1 in regulation of 
actin dynamics2. Activated LCP1 induced high cellular adhesion and increased actin 
binding and actin assembly2. 
LCP1 is found in many kinds of tumoral cells of non-hematopoietic origin, such as 
in the colon, prostate, and breast. LCP1 expression is correlated positively with advanced 
tumoral stages and severity in colon and breast cancers and is assumed a potential 
prognostic indicator3,4. Similar to those cancers, LCP1 is participated in tumoral invasion 
and metastasis in prostate cancer cells, and its knockdown experiment is potentially a 
useful approach for treating tumors1,5. In addition, cellular invasiveness of malignant 
melanoma cells requires not only LCP1 expression status but also the phosphorylation 
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levels of LCP16. However, the functional significance of LCP1 expression in OSCC for 
tumoral cellular proliferation and metastasis remains uncertain. 
In the present study, we sought to clarify the clinical relevance of LCP1 in oral squamous 
cell carcinomas (OSCCs) and valuate a new candidate for medical treatment of OSCCs 
by drug repositioning of an antibiotic agent. 
 
Results 
Up-Regulation of LCP1 in OSCC Cell Lines 
In order to evaluate the status of LCP1 expression as a cancer-related gene, we conducted 
real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) and 
immunoblot analyses with nine OSCC-derived cell lines and human normal oral 
keratinocytes (HNOKs). LCP1 mRNA expression was significantly up-regulated in all 
OSCC-derived cell lines compared with the HNOKs (Fig. 1A, P < 0.05). Figure 1B gives 
representative results of immunoblot analysis. The LCP1 protein also increased in all 
OSCC cell lines compared with the counterpart.  
 
Evaluation of LCP1 Status in Primary OSCCs 
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We evaluated the LCP1 expression in primary OSCCs by immunohistochemistry (IHC) 
and the IHC scoring system. The IHC scores of LCP1 in oral normal tissues and primary 
OSCCs ranged from 2.7 to 118.2 (median, 18.2) and 14.9 to 200.7 (median, 112.9). 
These IHC scores in primary OSCCs were significantly greater than in normal oral 
tissues (Fig. 1C, P < 0.05). Representative IHC figures for LCP1 protein in normal 
tissues, primary OSCCs, and metastatic lymph node were shown in Fig. 1D. Intense 
LCP1 immunoreactivity was observed in primary OSCCs and metastatic lymph nodes, 
whereas the normal oral tissues showed almost negative immunostaining.  
 
Establishment of LCP1 Knockdown Cells 
Because overexpression of LCP1 was frequently seen in OSCC in vitro and in vivo (Fig. 
1), we transfected LCP1 shRNA or shMock vectors into OSCC cells (Ca9-22, Ho-1-N-1). 
To investigate the efficiency of the transfection, we conducted qRT-PCR and 
immunoblot analyses. The LCP1 mRNA expression levels in the shLCP1 cells was lower 
than in the shMock cells (Fig. 2A, P < 0.05). Similarly, the LCP1 protein level in the 
shLCP1 cells decreased compared with the counterparts (Fig. 2B). To clarify the effect of 
LCP1 knockdown on localization of F-actin, we performed immunofluorescence (IF), 
which showed that LCP1 and F-actin were co-localized in the cytosol near the plasma 
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membrane in shMock cells, whereas LCP1 and F-actin were expressed throughout the 
cytosol in shLCP1 cells (Fig. 2C). 
 
Functional Assays 
A proliferation assay was performed to evaluate the effect of LCP1 knockdown on cell 
growth showed that the cell growth of shLCP1 cells was significantly inhibited compared 
with shMock cells after 120 h (Fig. 3A, P < 0.05; Student’s t-test). We also performed 
invasion and migration assays to evaluate the effect of LCP1 knockdown on cell 
invasiveness and migratory abilities. The number of invading shLCP1 cells significantly 
decreased compared with shMock cells after 48 h (Fig. 3B, P < 0.05; Student’s t-test), 
and the wound size significantly decreased in shMock cells after 12 h, whereas in the 
shLCP1 cells (Fig. 3C, P < 0.05; Student’s t-test).  
 
Enoxacin Treatment 
To investigate the efficiency of enoxacin (ENX), we assessed LCP1 expression and 
functional activities after treatment with ENX. Immunoblot analysis showed that LCP1 
protein levels in the ENX-treated cells decreased obviously compared with the control 
cells (optimal concentration, 125 μM) (Fig. 4A). The cell growth of the ENX-treated cells 
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was significantly inhibited compared with the control (Fig. 4B, P < 0.05, Student’s t-test). 
The number of ENX-treated cells invading the pores decreased significantly compared 
with the control (Fig. 4C, P < 0.05; Student’s t-test). In addition, the ENX-treated cells 
showed a wide gap after the 24h treatment (Fig. 4D). These results indicated that ENX 
might regulate critical functions associated with tumoral growth and metastasis through 
down-regulation of LCP1.  
 
Correlation between LCP1 Expression and Clinical Classification in OSCCs 
The correlations between the clinicopathologic features of OSCC cases and their LCP1 
protein levels using the IHC scoring system were shown in Table 1. To determine the 
optimal cutoff value of the IHC scores, we performed receiver operatorating 
characteristic curve (ROC curve) analysis, which showed that the optimal cutoff value 
was 115.1 for the primary tumoral size (area under the curve, 0.71; 95% confidence 
interval, 0.62-0.80; P < 0.05) and 85.2 for regional lymph node metastasis (area under 
the curve, 0.80; 95% confidence interval, 0.62-0.80; P < 0.05). Among the clinical 
classifications, the LCP1 expression level was related to the primary tumoral size and 
regional lymph node metastasis significantly (P < 0.05). 
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Discussion 
We found that LCP1 was overexpressed in OSCC in vitro and in vivo; LCP1 
knockdown cells decreased cell growth, invasiveness, and migratory activities; and 
LCP1 expression in clinical samples was associated positively with tumoral size and 
regional lymph node metastasis in OSCCs. Interestingly, we found that an oral 
broad-spectrum fluoroquinolone, ENX, controlled LCP1 expression, leading to similar 
phenotypes of LCP1 knockdown cells. 
Consistent with previous studies, the current study has shown the clinical 
relevance of LCP1 up-regulation, which is related closely to tumoral progression in 
various human cancers1,3-5. In malignant melanoma cells, invasiveness requires 
phosphorylation of LCP1 not up-regulation of LCP16. In addition to a previous study of 
prostate cancer progression1, our LCP1 knockdown models using OSCC cells is 
potentially useful to interfere with OSCC progression (Fig. 3). Because little is known 
about the detailed mechanism of LCP1 in tumoral growth and metastasis in human 
cancers, more studies are needed to better understand the important role of LCP1 in 
tumoral progression. 
 Metastatic cancer cells use actin bundles to invade from the primary tumoral site 
through the surrounding tissue4. Immunofluorescence data showed that localization of 
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F-actin, a binding partner of LCP1, was rearranged in shLCP1 cells (Fig. 2), which had 
low activity for cellular growth and tumoral invasion. These data suggested that the 
LCP1-F-actin complex has a critical role in proliferation and invasiveness of cancer 
cells. 
 ENX decreased cellular viability, induced apoptosis, caused cell cycle arrest, 
and inhibited the invasiveness in the prostate cancer cell lines7, making ENX an 
attractive candidate for use in cancer treatment as well as being an antibiotic. 
Comprehensive analysis using macrophages showed that LCP1 was down-regulated 
after treatment with ENX8, suggesting that ENX might regulate LCP1 expression. Our 
data indicated that ENX led to down-regulation of LCP1 and decreased cellular 
proliferation, invasiveness, and migratory activities. Further study is required to 
investigate if ENX is the upstream molecule of LCP1 in the cancer cells. 
  In conclusion, LCP1 seems to be a useful biomarker for determining the 
progression of OSCCs, and ENX might be a strong candidate as a new therapeutic agent 
against OSCCs by controlling LCP1 expression. 
 
Methods 
Ethics Statement 
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The ethics committee of Chiba University approved this study, protocol number, 236. We 
have obtained written informed consent from all subjects. 
 
OSCC-Derived Cell Lines and Tissue Specimens 
Nine OSCC-derived cell lines, including HSC-2 (RBRC-RCB1945, mouth), HSC-3 
(JCRB-0623, tongue), HSC-4 (RBRC-RCB1902, tongue), Sa3 (RBRC-RCB0980, upper 
gingiva), Ca9-22 (RCB-1976, gingiva), KOSC-2 (JCRB-0126.1, mouth floor), SAS 
(RBRC-RCB 1974, tongue), Ho-1-N-1 (JCRB-0831, buccal mucosa), and Ho-1-u-1 
(RBRC-RCB2102, mouth floor), were purchased from the JCRB cell bank (Ibaraki, 
Osaka, Japan) and the RIKEN BioResource Center (Tsukuba, Ibaraki, Japan). We used, 
as described previously, primary cultured HNOKs as a normal control cells and tissue 
specimens9-12. 
 
mRNA Expression Analysis 
We performed qRT-PCR as described previously 13-18. Briefly, the primer sequences 
were: LCP1, forward, 5’-AAC CCT CGA GTC AAT CAT TTG-3’; reverse, 5’-TTT 
GAT CTT TTC ATA GAG CTG GAA-3’; probe, #37. 
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Immunoblot Analysis 
Immunoblot analysis was conducted as described previously10,12,19-22. The antibodies 
were affinity-purified mouse anti-LCP1 monoclonal antibody (sc-133219, Santa Cruz 
Biotechnology), rabbit anti-GAPDH monoclonal antibody (sc-25778, Santa Cruz 
Biotechnology), and mouse anti-F-actin monoclonal antibody (ab205, Abcam). 
 
IHC 
IHC and IHC scoring systems were performed as described previously16,17,23-26. We 
quantified the intensity of the LCP1 immunoreaction with IHC profiler, 
(https://souceforge.net/projects/ihcprofiler/) 27. In order to determine the optimal cutoff 
point of LCP1 IHC scores, we evaluated the IHC scores from 121 samples with OSCC 
using the ROC curve analysis for each clinical parameter. Cases with a score over each 
cutoff point were defined as LCP1-positive 16,17,28-30.  
 
Transfection with shRNA Plasmid 
Transfection with shRNA Plasmid were conducted as described previously 11,16,17. LCP1 
shRNA (shLCP1) and control shRNA (shMock) vectors (sc-43209-SH, sc-108060, Santa 
Cruz Biotechnology) were transfected into Ca9-22 and Ho-1-N-1. After transfection, the 
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cells were isolated and cultured as previously described 11,16,17. To appraise the efficiency 
of LCP1 knockdown, we carried out qRT-PCR and immunoblotting. 
 
ENX Treatment 
ENX, a fluoroquinolone, has been used extensively and with minimal side effects in 
humans to treat urinary tract infections and gonorrhea8. Several investigators reported 
that ENX down-regulated LCP1, resulting in decreased formation of actin rings. 
Therefore, we challenged the cells with ENX for functional analyses, such as cellular 
proliferation, invasiveness, and migration assays. Since Sousa et al. reported the 
half-maximal effective concentrations (105 and 141 μM) of ENX for two prostate cancer 
cell lines7, we performed immunoblotting using ENX (Tokyo Chemical) ranged from 
concentrations of 1 to 150 μM to determine the optimal concentration for further 
functional analyses. 
 
Functional Assay 
Proliferation assay, invasion assay and migration assay was performed as described 
previously9,12,16,17,31-34.  
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Immunofluorescence Analysis 
IF was performed with a F-Actin Visualization Biochem Kit (Cytoskeleton) according to 
the manufacturer’s instructions and our protocol previously reported 17,34,35. IF was 
observed using confocal microscopy and analyzed with the FluoView Software (Olympus 
Optical)17,34,35. 
 
Statistical Analysis 
The statistical significance for LCP1 mRNA expression was calculated by the Student’s 
t-test. The correlations between the LCP1 IHC scores and each clinicopathological 
parameters were analyzed statistically by the χ2 test, Fisher’s exact test, and 
Mann-Whitney U-test. The significance level for two-sided P values was 0.05 for all tests. 
All data are expressed as the mean ± standard error of the mean of triplicate results. 
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Legends  
Figure 1. LCP1 expression in OSCC-derived cell lines and in primary OSCCs. (A) 
Quantification of LCP1 mRNA expression in OSCC-derived cell lines by qRT-PCR 
analysis. (B) Representative immunoblot analysis of LCP1 protein expression. 
Densitometric LCP1 protein data are normalized to GAPDH protein levels. The values 
are expressed as a percentage of the HNOKs. (C) The LCP1 IHC scores of normal oral 
tissues and OSCCs. (D) Representative IHC results for LCP1 protein in normal tissue, 
primary OSCCs, and metastatic regional lymph nodes. Original magnification, x 400. 
Scale bars, 50 μm.  
 
Figure 2. Establishment of LCP1 knockdown cells. (A) Expression of LCP1 mRNA in 
shMock and shLCP1 cells (Ca9-22 and Ho-1-N-1-derived transfectants). (B) Immunoblot 
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analysis of the LCP1 protein levels in shLCP1 cells and shMock cells. (C) 
Immunofluorescence of LCP1 and F-actin in shLCP1 cells and ahMock cells.  
 
Figure 3. Functional assays of LCP1 knockdown cells. (A) Proliferation assays of 
shMock cells and shLCP1 cells. The results are expressed as the mean ± standard error of 
the mean of the values from three assays. (B) Invasion assay of shMock cells and shLCP1 
cells. The mean value is calculated from data obtained from three separate chambers. (C) 
Migration assay of shMock cells and shLCP1 cells. The mean value is calculated from 
data obtained from three separate chambers. 
 
Figure 4. ENX treatment. (A) Immunoblot analysis of LCP1 protein levels in the 
ENX-treated cells. (B) Proliferation assay of the control and the ENX-treated cells. (C) 
Invasion assay of the control and the ENX-treated cells. (D) Migration assay of the 
control cells and the ENX-treated cells. 
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Table 1. Correlation between LCP1 expression and clinical classification in OSCCs. 
Clinical classification Total 
Immunostaining results 
No. patients P value 
LCP1-negative LCP1-positive 
Age at surgery (years)     
  <60 31 11 20  
  ≧60 90 24 66 0.445* 
Gender       Male 73 50 23 0.819†   Female 48 25 23 
T-primary tumor       T1+T2 46 28 18 0.019†‡   T3+T4 75 31 44 
N-regional lymph node    
  Negative 66 19 47 
0.023†‡ 
  Positive 55 6 49 
Vascular invasion    
  Negative 83 26       57 
0.080† 
  Positive 38  6 32 
Stage       I+ II 34 11 23 0.078†   III+ IV 87 14 73 
Histopathologic type       Well 80 20 60 
0.126§   Moderately 33 4 29 
  Poorly 8 1 7 
Tumoral site       Tongue  63 14 49 
0.087§ 
  Gingiva 36 9 27 
  Buccal mucosa 13 0 13 
  Oral floor 7 1 6 
  Lip 2 1 1 
*χ2 test. 
†Fisher’s exact test. 
‡P < 0.05. 
§Mann-Whitney U-test. 
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